Orthologous proteins contain sequence disparity guided by natural selection. In certain cases, species-specific protein functionality predicts pharmacological enhancement, such as greater specific activity or stability. However, immunological barriers generally preclude use of nonhuman proteins as therapeutics, and difficulty exists in the identification of individual sequence determinants among the overall sequence disparity. Ancestral sequence reconstruction (ASR) represents a platform for the prediction and resurrection of ancient gene and protein sequences. Recently, we demonstrated that ASR can be used as a platform to facilitate the identification of therapeutic protein variants with enhanced properties. Specifically, we identified coagulation factor VIII (FVIII) variants with improved specific activity, biosynthesis, stability, and resistance to anti-human FVIII antibody–based inhibition. In the current study, we resurrected a panel of ancient mammalian coagulation factor IX (FIX) variants with the goal of identifying improved pharmaceutical candidates. One variant (An96) demonstrated 12-fold greater FIX activity production than human FIX. Addition of the R338L Padua substitution further increased An96 activity, suggesting independent but additive mechanisms. after adeno-associated virus 2 (AAV2)/8-FIX gene therapy, 10-fold greater plasma FIX activity was observed in hemophilia B mice administered AAV2/8-An96–Padua as compared with AAV2/8-human FIX–Padua. Furthermore, phenotypic correction conferred by the ancestral variant was confirmed using a saphenous vein bleeding challenge and thromboelastography. Collectively, these findings validate the ASR drug discovery platform as well as identify an ancient FIX candidate for pharmaceutical development.
Flexible decision making is fundamental to day-to-day life. It often requires us to form expectations regarding the consequences of potential actions and to later retrieve those memories to guide choices. We used a task in which mice must develop, remember, and recall novel strategies to obtain rewards. Chemogenetically inactivating neurons within the orbitofrontal cortex (OFC) that are active during memory encoding obstructed later memory retrieval, impeding action flexibility. Meanwhile, stimulating these same neurons induced action flexibility. Thus, OFC neurons form stable memory traces (MTs) that are necessary and sufficient for action flexibility. Long-term storage of action variables may require new experiences to trigger durable cellular changes. Accordingly, MT neurons had higher proportions of mature dendritic spine types than neighboring non-MT neurons, this profile closely associated with successful learning. Further, activity of excitatory neurons and neurotrophin signaling within the basolateral amygdala were necessary for new memory formation and concurrent dendritic spine plasticity on MT neurons in the OFC. Thus, amygdalo-OFC interactions encode new reward information, which is retained by specific structurally-plastic neurons within the OFC and utilized during choice behavior.
Background: Acute myeloid leukemia (AML) remains the deadliest form of leukemia in children and adults despite therapeutic advances in recent decades. Chimeric antigen receptor (CAR) T-cell therapy is one such therapeutic approach that has been explored preclinically and clinically in AML; however, its efficacy is limited by antigen heterogeneity. To overcome this roadblock, we propose a dual-targeting CAR T-cell strategy, targeting the AML-associated antigens CD33 and CD70. Methods: To recapitulate tumor heterogeneity, we genetically edited the AML cell line Molm-13 using CRISPR-Cas9 to generate distinct sublines, namely CD33+/CD70−, CD33−/CD70+, and CD33+/CD70+. Two dual-targeting CAR T-cell approaches were developed: a “pooled” product, in which CAR T cells directed towards CD33 or CD70 are combined and co-administered, and a “co-transduced” product, wherein one population of T cells is transduced with both CD33-CAR- and CD70-CAR-encoding viral vectors. Results: Pooled and co-transduced products demonstrated potent cytotoxicity against all Molm-13 populations, whereas single-antigen CAR approaches were not as effective when their respective target antigen was absent. Mice engrafted with CD33/CD70 heterogeneous Molm-13 cells were treated with pooled or co-transduced CD33/CD70 CAR T cells. Both groups exhibited a significant survival advantage over the untreated group, with the co-transduced approach showing a statistically significant advantage over the pooled group. Conclusions: In summary, engineering one T cell to express both CARs yielded superior cytotoxicity when targeting a heterogeneous AML blast population.